CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions	Jul. 03, 2011		Dec. 31, 2010
Assets
Cash and cash equivalents	$ 3,096		$ 1,735
Short-term investments	22,388		26,277
Accounts receivable, less allowance for doubtful accounts	15,192		14,426
Short-term loans	462		467
Inventories	8,597	[1],[2]	8,275	[1],[2]
Taxes and other current assets	9,271		8,394
Assets of discontinued operations and other assets held for sale	1,478		1,439
Total current assets	60,484		61,013
Long-term investments and loans	10,207		9,747
Property, plant and equipment, less accumulated depreciation	18,281		18,645
Goodwill	45,107		43,928
Identifiable intangible assets, less accumulated amortization	57,059	[3]	57,555	[3]
Taxes and other noncurrent assets	4,761		4,126
Total assets	195,899		195,014
Liabilities and Shareholders' Equity
Short-term borrowings, including current portion of long-term debt	5,988	[4]	5,603	[4]
Accounts payable	3,698		3,994
Dividends payable	1,637		1,601
Income taxes payable	1,849		951
Accrued compensation and related items	1,815		2,080
Other current liabilities	15,303		14,256
Liabilities of discontinued operations	181		151
Total current liabilities	30,471		28,636
Long-term debt	35,723	[5],[6]	38,410	[5],[6]
Pension benefit obligations	5,852		6,194
Postretirement benefit obligations	3,057		3,035
Noncurrent deferred tax liabilities	20,072		18,628
Other taxes payable	6,829		6,245
Other noncurrent liabilities	4,932		5,601
Total liabilities	106,936		106,749
Preferred stock	47		52
Common stock	445		444
Additional paid-in capital	71,095		70,760
Employee benefit trusts	(3)		(7)
Treasury stock	(26,471)		(22,712)
Retained earnings	44,320		42,716
Accumulated other comprehensive loss	(952)		(3,440)
Total Pfizer Inc. shareholders' equity	88,481		87,813
Equity attributable to noncontrolling interests	482		452
Total shareholders' equity	88,963		88,265
Total liabilities and shareholders' equity	$ 195,899		$ 195,014

[1] Certain amounts of inventories are in excess of one year's supply. There are no recoverability issues associated with these quantities.

[2] The increase reflects the impact of foreign exchange as well as increases associated with the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc. for additional detail) partially offset by reductions in the normal course of business.

[3] The decrease is primarily related to amortization as well as impairment charges (see Note 6. Other (Income)/Deductions-Net) of intangible assets, partially offset by the assets acquired as part of the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.) and the impact of foreign exchange.

[4] The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant at July 3, 2011 or December 31, 2010.

[5] Includes foreign currency debt with fair values of $881 million at July 3, 2011 and $880 million at December 31, 2010, which are used to hedge the exposure of certain foreign currency denominated net investments.

[6] The fair value of our long-term debt is $39.2 billion at July 3, 2011 and $42.3 billion at December 31, 2010.